Leading Scientists Demonstrate How Seer's Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026
MWN-AI** Summary
At the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, Seer, Inc. showcased its Proteograph® Product Suite as a transformative tool for advancing cardiovascular and neurodegenerative research. With a focus on providing deep, unbiased proteomic insights, Seer participated from February 21-25 in St. Louis, engaging in more than a dozen scientific presentations, including posters and oral sessions.
The conference highlighted how Seer’s technology addresses complex health questions while meeting the expanding needs of clinical and population health applications. Researchers applied the Proteograph Suite to diverse areas such as cardiovascular disease, neurodegeneration, oncology, and aging biology, demonstrating its capability to link laboratory findings with human health impacts.
Notably, Dr. Sasha A. Singh from Harvard Medical School presented research on atherosclerosis, revealing that using just 75 µL of plasma could yield quantification of over 5,000 proteins. This significant achievement—representing a tenfold increase in proteomic depth—illustrates Proteograph's utility in overcoming longstanding challenges associated with low-abundance proteins.
Additionally, the conference featured Dr. Nathan Basisty from the National Institute on Aging, discussing how proteomic advancements are paving the way for breakthroughs in aging biology and therapeutic strategies. Throughout the event, Seer's technology was emphasized in numerous discussions, showing the breadth of its impact across various disease models and its capacity for high-throughput proteomic analysis.
As Seer continues to drive innovation in proteomics, the 2026 US HUPO conference served as a crucial platform for illustrating how deep, scalable proteomic technologies are revolutionizing translational research and healthcare outcomes. Attendees were encouraged to connect with the Seer team at Booth #18 for further insights into this cutting-edge science.
MWN-AI** Analysis
As Seer, Inc. (Nasdaq: SEER) showcases its Proteograph® Product Suite at the US HUPO 2026 conference, market analysts should take notice of the implications for the company's growth in the proteomics sector. The presentations highlighted at this event underscore a growing demand for advanced proteomic technologies, particularly in addressing pressing research needs in cardiovascular and neurodegenerative diseases.
The ability of Seer's Proteograph to increase proteome depth significantly—achieving more than a tenfold increase in quantification capability—positions the company as a leader in this space. With strong validation from various research applications across multiple disease areas, Seer is well-positioned to capture increased market share within both academic and commercial research. This advancement reflects a broader industry trend towards scalable, reproducible proteomics, which is becoming essential for translating scientific discovery into clinical applications.
Investors should consider the potential for Seer's innovations to lead to partnerships with pharmaceutical and biotech companies, particularly as interest in personalized medicine rises. The strategic importance of Seer's technology in transforming proteomic research aligns well with future growth trends in healthcare, where biomarkers and early disease detection are paramount.
As the market responds to Seer's advancements, investors might want to monitor stock performance closely, especially following high-profile presentations at events like US HUPO. The increased visibility of Seer’s technologies could catalyze share price growth, particularly if ongoing research yields positive results that impact therapeutic strategies.
In conclusion, maintaining a bullish outlook on Seer, Inc. appears prudent, as the company continues to expand its influence and operational capacity in the burgeoning field of proteomics, poised for significant growth in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
REDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At the meeting, researchers will demonstrate how Seer’s Proteograph® Product Suite is enabling them to tackle complex questions in major disease areas, while supporting the scaling requirements needed for clinical and population health applications.
US HUPO has emerged as an important venue for evaluating how new proteomic technologies perform when applied to real-world research challenges. At US HUPO 2026, Seer will be featured across more than a dozen scientific presentations spanning posters, oral sessions, and plenary talks, reflecting the growing adoption of nanoparticle-enabled proteomics across translational and population-scale research. This year’s presentations span cardiovascular disease, neurodegeneration, aging biology, oncology, and computational advances, underscoring how deep, scalable proteomics is helping bridge laboratory discovery with human health outcomes.
Attendees can connect with the Seer team at Booth #18, explore poster presentations featuring biological insights enabled by the Proteograph Product Suite, and attend a breakfast symposium highlighting breakthrough findings in cardiovascular disease research.
"The work being presented at US HUPO reflects a broader shift in proteomics toward deeper, more scalable, and more reproducible mass spectrometry measurement of the human proteome that is enabled by the Proteograph Product Suite," said David Horn, President and Chief Financial Officer at Seer. "As researchers apply the Proteograph solution to their complex disease models and large-scale cohorts, we are seeing strong validation of the Proteograph’s scientific impact and its strategic importance to advancing translational research at scale.”
Seer Breakfast Symposium
Nanoparticle-Enabled Plasma Proteomics of a Mouse Atherosclerosis Model
Date: Tuesday, February 24 | Time: 7:15–8:15 a.m. CT | Location: Room Grand GH
Speaker: Sasha A. Singh, PhD, Assistant Professor of Medicine, Harvard Medical School
In Tuesday’s symposium, Dr. Singh will present how her laboratory applied the Proteograph Product Suite to deeply profile plasma in a murine model of atherosclerosis, addressing long-standing challenges in detecting low-abundance proteins from small-volume samples. Using just 75 µL of plasma per sample, the workflow enabled reproducible quantification of more than 5,000 proteins, representing more than a tenfold increase in proteome depth compared with conventional approaches.
US HUPO Plenary Session Highlight
Nathan Basisty, PhD, NIH Distinguished Scholar and Tenure Track Investigator at the National Institute on Aging, will present during the Robert J. Cotter New Investigator Award Plenary Session on Tuesday, February 24 (8:30–9:05 a.m. CT). His talk, Paving the Road to Translational Geroscience with Proteomics, will explore how advances in proteomic technologies are accelerating the translation of aging biology into biomarkers and therapeutic strategies.
Additional Scientific Presentations Featuring Seer Technology
Seer-enabled research will be featured across a broad set of oral presentations, plenary sessions, and posters throughout US HUPO 2026, highlighting the application of deep, scalable proteomics to cardiovascular disease, neurodegeneration, oncology, aging biology, and population-scale workflows.
Invited Speaker Presentations
- Pathways and Pitfalls in Translating Multi-Omics Discoveries into a Protein-Based LDT for Lung Cancer
Bruce Wilcox, PrognomiQ
February 24 | 9:15 AM | Room Grand DE
- Linking Tissue-Specific Senescence Burden to Circulating Protein Signatures Using a Novel Nanoparticle-Based Enrichment Workflow
Mozhgan Boroumand, National Institute on Aging, NIH
February 24 | 9:57 AM | Room Grand DE
Oral and Poster Presentations
- Unbiased Deep Proteomic Profiling of Conditioned Media and Cerebrospinal Fluid Using a Nanoparticle-Based Workflow
Presenter: A. Gajadhar | Poster Session 1 | February 23, 4:30–6:30 PM CT - Systematic Proteomic Architecture of Neurodegeneration Reveals Translation and Vesicular Dysregulation as Upstream Drivers of Neuronal Decline
Presenter: A. Siddiqui | Poster Session 1 | February 23, 4:30–6:30 PM CT - Evaluating Nanoparticle-Based Enrichment of Cell Lysates for Automated, Global Proteome Analysis
Presenter: E. Stancliffe | Poster Session 1 | February 23, 4:30–6:30 PM CT
- Addressing the Plasma Proteomics Needs of Large-Scale Clinical Cohorts
Presenter: C. Kempf | Poster Session 1 | February 23, 4:30–6:30 PM CT - Accelerating Biomarker Discovery with High-Depth, Whole Patient Multimodal Proteomics and Transcriptomics
Presenter: D. Gutierrez | Poster Session 1 | February 23, 4:30–6:30 PM CT
- From Peaks to Power: Context-Driven Determinants of Accuracy in Biologically Resolved Proteomics
Presenter: L. Cantrell | Poster Session 2 | February 24, 4:30–6:30 PM CT - A Cloud-Native Pipeline Enabling Fast, Sensitive, and Accurate Quantitative DIA Proteomics for Thousands of Samples
Presenter: S. Just | Poster Session 2 | February 24, 4:30–6:30 PM CT - Comprehensive Plasma Proteomic Analysis of Systemic Changes Following Chemotherapy in Breast Cancer Patients
Presenter: L. Herring | Poster Session 2 | February 24, 4:30–6:30 PM CT - Aging-Associated Plasma Proteome Changes in Healthy Non-Human Primates
Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT - An Optimized Workflow for Plasma Proteomics
Presenter: D. Key Planas | Poster Session 2 | February 24, 4:30–6:30 PM CT
Together, these presentations reflect the expanding role of Proteograph-enabled workflows in advancing biological insight across disease areas while supporting reproducible, high-throughput proteomics at scale.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please visit Booth #18 at US HUPO 2026 or contact us at pr@seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Kelly Gura
investor@seer.bio
FAQ**
How is Seer Inc. SEER's Proteograph Product Suite positioned to address the challenges in proteomics highlighted during the US HUPO 2026 conference, particularly in applications related to cardiovascular disease and neurodegeneration?
What specific advancements in nanoparticle-enabled proteomics did Seer Inc. SEER showcase at US HUPO 20that demonstrate its potential impact on clinical and population health applications?
In what ways is Seer Inc. SEER's involvement at the US HUPO 2026 conference likely to influence investor confidence in the company's future growth and its role in advancing translational research?
Can you elaborate on how the findings shared by Seer Inc. SEER during US HUPO 2026 may lead to new biomarker discoveries and therapeutic strategies in aging and oncology?
**MWN-AI FAQ is based on asking OpenAI questions about Seer Inc. (NASDAQ: SEER).
NASDAQ: SEER
SEER Trading
-2.72% G/L:
$1.79 Last:
94,376 Volume:
$1.81 Open:
